Skip to main content
Board-Certified Psychiatrist (ABPN)U.S. + Israel LicensedTelepsychiatry since 2013Psychiatrist present during every IM sessionPrescription treatment · Ages 18+ · Medical evaluation required

Desktop Recommended for Best Experience

For the best experience completing forms, assessments, and navigating patient resources, we recommend using a desktop or laptop computer.

This site is informational. Treatment requires full medical evaluation. Not for emergencies — if in crisis, contact local emergency services or a crisis line.
Visual Neuroscience Library · Episode 7

Glutamate → AMPA → BDNF: A Conceptual Pathway

The Molecular Cascade Behind Ketamine's Plasticity-Promoting Effects

2 min

Researchers have proposed a simplified molecular pathway to help explain how a single ketamine dose may rapidly promote neural plasticity. In this model, ketamine blocks NMDA receptors, shifting glutamate signaling in a way that boosts AMPA receptor activity. This is thought to trigger the release of BDNF — a growth factor that supports the growth and strengthening of synaptic connections. This cascade is one of several frameworks scientists use to understand ketamine's effects; it is conceptual and simplified, not a complete picture.

What is reasonably well supported

• Ketamine blocks NMDA-type glutamate receptors, which is its best-characterized pharmacological action. • Increased AMPA receptor signaling and downstream release of BDNF are documented in preclinical models following ketamine. • BDNF supports synaptogenesis (the formation of new synaptic connections), including in the prefrontal cortex. • The glutamate–AMPA–BDNF cascade is a widely cited framework in the ketamine antidepressant literature.

What remains uncertain

• Whether this single pathway fully accounts for ketamine's clinical effects, which likely involve multiple mechanisms. • How directly the molecular cascade in animal models translates to human therapeutic outcomes. • The relative contribution of ketamine's metabolites (e.g., hydroxynorketamine) to plasticity. • Whether BDNF levels measured in blood reliably reflect the brain changes relevant to treatment response.

Clinical framing

The glutamate–AMPA–BDNF pathway offers a useful story for understanding why ketamine may promote plasticity, but it is a simplification. Ketamine should not be presented as "boosting BDNF," "growing new brain cells," or "rebuilding the brain." Clinically, the value of this framework is that it underscores ketamine as a potential opener of a plasticity window — one that therapeutic work and integration can help translate into lasting change.

References and further reading

Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling

Pending review

Cavalleri L, Merlo Pich E, Millan MJ, Chiamulera C, Kunath T, Spano PF, Collo G

Molecular Psychiatry· 2018Reference

Translational cell study using mouse and human iPSC-derived dopaminergic neurons, supporting AMPAR/BDNF/mTOR-linked structural plasticity. Added as supporting evidence; pending clinician review.

View sourceDOI: 10.1038/mp.2017.241

Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites

Pending review

Yang C, Yang J, Luo A, Hashimoto K

Translational Psychiatry· 2019Review

Mechanistic review emphasizing AMPA, BDNF/TrkB, mTOR/ERK, enantiomer and metabolite complexity; supports presenting the cascade as one model rather than a complete mechanism. Added as supporting evidence; pending clinician review.

View sourcePMID: 31699965; DOI: 10.1038/s41398-019-0624-1

Synaptic dysfunction in depression: potential therapeutic targets

Verified

Duman RS, Aghajanian GK

Science· 2012Review

Landmark review (Science, 2012;338:68-72) describing the glutamate–AMPA–BDNF–synaptic plasticity cascade thought to underlie ketamine's antidepressant effects. Verified via PubMed.

View sourcePMID: 23042884 · DOI: 10.1126/science.1222939

This content is educational and does not constitute medical advice, a treatment recommendation, or a guarantee of outcome. All diagrams and explanations are conceptual and simplified for general understanding. They are not direct representations of individual patient data. Continuing to psychiatric treatment requires secure intake, clinician review, and a full psychiatric evaluation; the orientation conversation is informational only. Research on ketamine's effects on brain networks is active and evolving.

Want to learn if KAP is right for you?

Start with a free 15–20 minute KAP orientation conversation.

Book Free KAP Orientation →